Literature DB >> 9463680

Oral fluoroquinolones for maintenance treatment of melioidosis.

W Chaowagul1, Y Suputtamongkul, M D Smith, N J White.   

Abstract

Ciprofloxacin (20 mg/kg/d) or ofloxacin (12 mg/kg/d) given for a median of 15 weeks (range 12-40) were used for maintenance treatment of 57 adult patients with melioidosis. The median duration of follow-up in the 45 patients who complied with treatment and were followed for at least 6 months was 28 months (range 6-65). Fluoroquinolone treatment was well tolerated. There were 13 treatment failures (5 failures to respond, 8 relapses), a failure rate of 29% (95% confidence interval 17-43%). The median time to treatment failure was 7 months (range 2-26). These results are inferior to those with courses lasting 20 weeks of amoxycillin/clavulanic acid or the combination of chloramphenicol, doxycycline and trimethoprim/sulphamethoxazole, and suggest that the fluoroquinolones should be reserved as third line agents, and not used for the maintenance treatment of melioidosis unless there is resistance to, or intolerance of, the other available antimicrobial compounds.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9463680     DOI: 10.1016/s0035-9203(97)90044-4

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  22 in total

Review 1.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

2.  Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand.

Authors:  Vanaporn Wuthiekanun; Premjit Amornchai; Natnaree Saiprom; Narisara Chantratita; Wirongrong Chierakul; Gavin C K W Koh; Wipada Chaowagul; Nicholas P J Day; Direk Limmathurotsakul; Sharon J Peacock
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

3.  Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance.

Authors:  Linnell B Randall; Enrico Georgi; Gelimer H Genzel; Herbert P Schweizer
Journal:  J Antimicrob Chemother       Date:  2017-04-01       Impact factor: 5.790

4.  Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis.

Authors:  Wipada Chaowagul; Wirongrong Chierakul; Andrew J Simpson; Jennifer M Short; Kasia Stepniewska; Bina Maharjan; Adul Rajchanuvong; Duangkaew Busarawong; Direk Limmathurotsakul; Allen C Cheng; Vanaporn Wuthiekanun; Paul N Newton; Nicholas J White; Nicholas P J Day; Sharon J Peacock
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  In vitro susceptibilities of Burkholderia mallei in comparison to those of other pathogenic Burkholderia spp.

Authors:  D J Kenny; P Russell; D Rogers; S M Eley; R W Titball
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 6.  Melioidosis: epidemiology, pathophysiology, and management.

Authors:  Allen C Cheng; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

7.  Recurrent melioidosis in patients in northeast Thailand is frequently due to reinfection rather than relapse.

Authors:  Bina Maharjan; Narisara Chantratita; Mongkol Vesaratchavest; Allen Cheng; Vanaporn Wuthiekanun; Wirongrong Chierakul; Wipada Chaowagul; Nicholas P J Day; Sharon J Peacock
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

8.  Outcomes of patients with melioidosis treated with cotrimoxazole alone for eradication therapy.

Authors:  Sarunyou Chusri; Thanaporn Hortiwakul; Boonsri Charoenmak; Khachornsakdi Silpapojakul
Journal:  Am J Trop Med Hyg       Date:  2012-10-01       Impact factor: 2.345

9.  Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei.

Authors:  Sharon J Peacock; Herbert P Schweizer; David A B Dance; Theresa L Smith; Jay E Gee; Vanaporn Wuthiekanun; David DeShazer; Ivo Steinmetz; Patrick Tan; Bart J Currie
Journal:  Emerg Infect Dis       Date:  2008-07       Impact factor: 6.883

10.  Comparison of the in vitro and in vivo susceptibilities of Burkholderia mallei to Ceftazidime and Levofloxacin.

Authors:  Barbara M Judy; Gregory C Whitlock; Alfredo G Torres; D Mark Estes
Journal:  BMC Microbiol       Date:  2009-05-09       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.